ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,521 to 4,540 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Sulopenem vs Ertapenem: deaths from any cause2 of 697

0 of 698

0.3 points

-0.3 to 1.0

1,395NCT03357614

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

Sulopenem vs Ertapenem: serious adverse events14 of 697

6 of 698

1.1 points

-0.1 to 2.6

1,395NCT03357614

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

Rimegepant vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Primary Analysis102 of 135

979 of 1,260

-2.1 points

-10.3 to 4.8

1,395NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Primary Analysis36 of 135

334 of 1,260

0.2 points

-7.0 to 8.5

1,395NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant vs Triptans: Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis132 of 135

1,228 of 1,260

0.3 points

-3.9 to 2.1

1,395NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant vs Triptans: Number of Participants With Cardiologist Visits in Past 6 Month- Primary Analysis21 of 135

130 of 1,260

5.2 points

-0.2 to 12.5

1,395NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant vs Triptans: Number of Participants With Hospitalizations in Past 6 Months- Primary Analysis15 of 135

147 of 1,260

-0.6 points

-5.2 to 6.1

1,395NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Rimegepant vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis72 of 135

374 of 1,260

23.7 points

14.9 to 32.2

1,395NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Antiretroviral Therapy (ART) Adherence466 of 767

200 of 627

28.9 points

23.7 to 33.8

1,394NCT04571684

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Number of Participants Receiving Complete PMTCT60 of 767

22 of 627

4.3 points

1.9 to 6.7

1,394NCT04571684

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Antenatal Viral Load (VL) Test Coverage330 of 767

137 of 627

21.2 points

16.3 to 25.8

1,394NCT04571684

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Postnatal Viral Load (VL) Test Coverage518 of 767

371 of 627

8.4 points

3.3 to 13.4

1,394NCT04571684

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

CT Coronary Angiography-based Rapid Rule Out (Group B) vs Traditional Strategy (Group A): deaths from any cause2 of 929

3 of 463

-0.4 points

-1.7 to 0.3

1,392NCT00933400

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

CT Coronary Angiography-based Rapid Rule Out (Group B) vs Traditional Strategy (Group A): serious adverse events0 of 929

2 of 463

-0.4 points

-1.6 to 0.1

1,392NCT00933400

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: Objective Response Rate (ORR)120 of 694

71 of 697

7.1 points

3.5 to 10.7

1,391NCT00312377

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: Disease Control Rate (DCR)413 of 694

380 of 697

5.0 points

-0.2 to 10.2

1,391NCT00312377

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events263 of 694

232 of 697

4.6 points

-0.4 to 9.6

1,391NCT00312377

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Segment Binary Angiographic Restenosis102 of 1,062

76 of 328

-13.6 points

-18.7 to -8.9

1,390NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Single Injection of 150 µg SCH 900962/MK-8962 vs Daily 300 IU recFSH: Number of Participants Who Cancelled the Cycle Due to a (Serious) Adverse Event5 of 692

6 of 698

-0.1 points

-1.2 to 0.9

1,390NCT01144416

Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)

Single Injection of 150 µg SCH 900962/MK-8962 vs Daily 300 IU recFSH: Number of Participants With Moderate or Severe Ovarian Hyperstimulation Syndrome (OHSS)5 of 692

10 of 698

-0.7 points

-2.0 to 0.4

1,390NCT01144416

Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=227"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=227

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03357614-deaths",
        "title": "Sulopenem vs Ertapenem: deaths from any cause",
        "summary": "2 of 697 against 0 of 698; risk difference 0.3 points, 95% interval -0.3 to 1.0; NCT03357614, Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults",
        "record": "/library/comparisons/NCT03357614-deaths",
        "nct_id": "NCT03357614",
        "kind": "deaths",
        "participants": 1395,
        "risk_difference": {
          "value": 0.0028694404591104736,
          "lower": -0.002986632603831936,
          "upper": 0.010401377262710282
        },
        "group_1": "2 of 697",
        "group_2": "0 of 698",
        "difference": "0.3 points",
        "interval": "-0.3 to 1.0",
        "trial_title": "Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults"
      },
      {
        "id": "NCT03357614-sae",
        "title": "Sulopenem vs Ertapenem: serious adverse events",
        "summary": "14 of 697 against 6 of 698; risk difference 1.1 points, 95% interval -0.1 to 2.6; NCT03357614, Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults",
        "record": "/library/comparisons/NCT03357614-sae",
        "nct_id": "NCT03357614",
        "kind": "serious-adverse-events",
        "participants": 1395,
        "risk_difference": {
          "value": 0.011490094675091364,
          "lower": -0.0013921540065003,
          "upper": 0.02562239127095186
        },
        "group_1": "14 of 697",
        "group_2": "6 of 698",
        "difference": "1.1 points",
        "interval": "-0.1 to 2.6",
        "trial_title": "Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=228",
  "request_id": "u2lHWVCe-L4-C8sz"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?